Programs
Biomedical Research Leadership
PMSF IS A LEADER IN BIOMEDICAL RESEARCH IN PUERTO RICO AND IS COMPRISED OF HIGHLY ACCOMPLISHED RESEARCHES WITH EXPERTISE IN CANCER, NEUROSCIENCE, HIV AND MENTAL HEALTH. PMSF PROVIDES MODERN RESEARCH FACILITIES THAT FOSTER COLLABORATIVE, INTEGRATIVE BASIC AND CLINICAL RESEARCH. PMSF HOUSES ONE OF THE TOP CLINICAL TRIAL RESEARCH SITES IN PUERTO RICO, THE ONLY CANCER TISSUE REPOSITORY FOR PUERTO RICAN PATIENTS.GeographiesNot indicatedDatesJul 1, 2021 – Jun 30, 2022Source990No causes providedNo populations provided–$19.6MResearch Opportunities in Public Health
THE INSTITUTION HAS PROVIDED EDUCATIONAL AND RESEARCH OPPORTUNITIES FOR PHYSICIANS, PSYCHOLOGISTS, PUBLIC HEALTH AND BIOMEDICAL STUDENTS INTERESTED IN PURSUING RESEARCH CAREERS. PMSF IS A KEY PLAYER IN ONGOING RESEARCH INITIATIVES ON CHIKUNGUYA, DENGUE, AND ZIKA AS IT HOUSES THE MOST COMPREHENSIVE DATABASE. PMSF THROUGH INNO DIAGNOSTICS, A CLIA-CERTIFIED DIAGNOSTIC TESTING LABORATORY, HAS PLAYED A PIVOTAL ROLE IN PROVIDING MOLECULAR TESTING AND VACCINES ADMINISTRATION TO THE SOUTH OF PUERTO RICO DURING THE COVID-19 PANDEMIC. AS OF JUNE 30, 2022, OVER 82,000 PATIENTS FROM SOUTHERN PUERTO RICO HAVE BENEFITED FROM THIS SERVICE, WHICH IS CURRENTLY ONGOING. ALSO, PMSF WERE AWARDED FEDERAL AND PRIVATE GRANTS TO WORK WITH COVID-19 RESEARCH INITIATIVES. PMSF IS ACTIVELY ENGAGED IN IMPROVING THE COMMUNITY'S WELL-BEING AND PARTICIPATING IN IMPORTANT SOCIAL INITIATIVES.GeographiesNot indicatedDatesJul 1, 2021 – Jun 30, 2022Source990No causes providedNo populations provided––Program 1 [2024]
PMSF IS A LEADER IN BIOMEDICAL RESEARCH IN PUERTO RICO AND IS COMPRISED OF HIGHLY ACCOMPLISHED RESEARCHERS WITH EXPERTISE IN CANCER, NEUROSCIENCE, HIV AND MENTAL HEALTH. PMSF PROVIDES MODERN RESEARCH FACILITIES THAT FOSTER COLLABORATIVE, INTEGRATIVE BASIC AND CLINICAL RESEARCH. PMSF HOUSES ONE OF THE TOP CLINICAL TRIAL RESEARCH SITES IN PUERTO RICO, THE ONLY CANCER TISSUE REPOSITORY FOR PUERTO RICAN PATIENTS.GeographiesNot indicatedDatesJul 1, 2023 – Jun 30, 2024Source990No causes providedNo populations provided–$17M
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)